The UK Antimicrobial Registry (UKAR) is being developed by the British Society for Antimicrobial Chemotherapy (BSAC) to provide prescribers and organisations the opportunity to capture real world usage of antimicrobial agents and identify where the real clinical unmet need lies. This will provide an invaluable resource for future research studies and also enable the sharing of best practice.
The Registry will be a collaborative epidemiological study through which BSAC will work with one academic and several industry partners. It will be a central activity through which BSAC and partners will support the antimicrobial community in increasing positive outcomes for patients while helping to contain and control the threat of antimicrobial resistance. The Registry will initially be open for intravenous antibiotics, with a particular focus on those used to treat infections due to multi-drug resistant organisms.
A team from the University of Aberdeen Institute of Applied Health Sciences, led by Prof Gary Macfarlane, have been appointed as academic partner and bring experience in Registry development and evaluation. Several industry partners have committed support for the project.
The registry will be overseen by the multi-stakeholder UKAR Management Committee to ensure appropriate consent and governance at all levels of implementation. BSAC has appointed Dr Jacqueline Sneddon as Programme Manager for this work and will also utilise a multi-professional BSAC UKAR Study Management Team to provide infection expertise for the project.
The project will begin recruitment of collaborating centres towards the end of 2022 and will provide an exciting opportunity for hospitals across the UK to be part of a programme with national and international importance.
If your hospital is interested in getting involved in the UKAR project please complete and submit the contact form below.